Logo image of IMRN

IMMURON LTD-SPON ADR (IMRN) Stock Fundamental Analysis

NASDAQ:IMRN - Nasdaq - US45254U1016 - ADR - Currency: USD

1.9  +0.01 (+0.53%)

Fundamental Rating

3

Overall IMRN gets a fundamental rating of 3 out of 10. We evaluated IMRN against 572 industry peers in the Biotechnology industry. While IMRN seems to be doing ok healthwise, there are quite some concerns on its profitability. IMRN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IMRN had negative earnings in the past year.
IMRN had a negative operating cash flow in the past year.
In the past 5 years IMRN always reported negative net income.
IMRN had a negative operating cash flow in each of the past 5 years.
IMRN Yearly Net Income VS EBIT VS OCF VS FCFIMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

IMRN's Return On Assets of -44.61% is in line compared to the rest of the industry. IMRN outperforms 50.62% of its industry peers.
With a decent Return On Equity value of -54.58%, IMRN is doing good in the industry, outperforming 62.70% of the companies in the same industry.
Industry RankSector Rank
ROA -44.61%
ROE -54.58%
ROIC N/A
ROA(3y)-24.44%
ROA(5y)-30.3%
ROE(3y)-28.73%
ROE(5y)-34.09%
ROIC(3y)N/A
ROIC(5y)N/A
IMRN Yearly ROA, ROE, ROICIMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

IMRN has a Gross Margin of 68.06%. This is amongst the best in the industry. IMRN outperforms 81.88% of its industry peers.
In the last couple of years the Gross Margin of IMRN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for IMRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.56%
GM growth 5Y-1.13%
IMRN Yearly Profit, Operating, Gross MarginsIMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

IMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMRN has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for IMRN has been increased compared to 5 years ago.
Compared to 1 year ago, IMRN has a worse debt to assets ratio.
IMRN Yearly Shares OutstandingIMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
IMRN Yearly Total Debt VS Total AssetsIMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

IMRN has an Altman-Z score of -3.10. This is a bad value and indicates that IMRN is not financially healthy and even has some risk of bankruptcy.
IMRN's Altman-Z score of -3.10 is in line compared to the rest of the industry. IMRN outperforms 46.36% of its industry peers.
IMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.1
ROIC/WACCN/A
WACC9.33%
IMRN Yearly LT Debt VS Equity VS FCFIMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 5.46 indicates that IMRN has no problem at all paying its short term obligations.
The Current ratio of IMRN (5.46) is comparable to the rest of the industry.
IMRN has a Quick Ratio of 4.87. This indicates that IMRN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.87, IMRN is in line with its industry, outperforming 54.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.46
Quick Ratio 4.87
IMRN Yearly Current Assets VS Current LiabilitesIMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

IMRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -83.15%.
Looking at the last year, IMRN shows a very strong growth in Revenue. The Revenue has grown by 171.67%.
IMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.48% yearly.
EPS 1Y (TTM)-83.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-168.77%
Revenue 1Y (TTM)171.67%
Revenue growth 3Y222.79%
Revenue growth 5Y15.48%
Sales Q2Q%108.61%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMRN Yearly Revenue VS EstimatesIMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
IMRN Yearly EPS VS EstimatesIMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMRN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMRN Price Earnings VS Forward Price EarningsIMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMRN Per share dataIMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IMRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMURON LTD-SPON ADR

NASDAQ:IMRN (2/21/2025, 8:00:01 PM)

1.9

+0.01 (+0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28 2024-08-28
Earnings (Next)02-26 2025-02-26
Inst OwnersN/A
Inst Owner Change-44.87%
Ins Owners7.62%
Ins Owner ChangeN/A
Market Cap10.83M
Analysts0
Price TargetN/A
Short Float %0.43%
Short Ratio1.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.46
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0.55
BVpS1.42
TBVpS1.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.61%
ROE -54.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.06%
FCFM N/A
ROA(3y)-24.44%
ROA(5y)-30.3%
ROE(3y)-28.73%
ROE(5y)-34.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.56%
GM growth 5Y-1.13%
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.46
Quick Ratio 4.87
Altman-Z -3.1
F-Score3
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.58%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-83.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-168.77%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)171.67%
Revenue growth 3Y222.79%
Revenue growth 5Y15.48%
Sales Q2Q%108.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-125.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.58%
OCF growth 3YN/A
OCF growth 5YN/A